Orthocell has today released its Quarterly Report for the period ended 31 December 2025 – a quarter marked by continued revenue growth and accelerating U.S. commercialisation.Key highlights for the quarter include:
Seventh consecutive quarter of record revenue of $3.2 million, driven by Remplir’s growing penetration across existing markets and initial U.S. sales.
Strong financial position, with cash reserves of $49.4 million as at 31 December 2025, following a successful $30 million institutional capital raise.
US commercialisation ahead of expectations, with distributor coverage now spanning 25+ states and reaching 40% of the U.S. population, and the first 100 US sales achieved.
Progress across new markets, including Canada and Hong Kong, with first Canadian sales expected in CY26.
Regulatory application submitted for the EU and UK nerve repair markets, with approval expected in 3Q CY26.
Expanded complementary product portfolio, otherwise global distribution rights to PearlBone™ bone regeneration technology.
Momentum continues for prostate nerve-sparing surgery opportunity with ~100 Remplir procedures completed.
